Cibus and Biographica are collaborating to enhance disease resistance in oilseed rape and Canola using AI-driven gene editing.
Quiver AI Summary
Cibus, Inc. and Biographica have announced a collaboration aimed at enhancing disease resistance in oilseed rape and Canola through gene editing. Utilizing Biographica's advanced AI platform, the partnership will identify and prioritize gene targets related to disease resistance, facilitating the development of improved crop varieties. Both companies are committed to pushing the boundaries of agricultural innovation, with the goal of creating more resilient crops that can withstand various diseases, ultimately benefiting farmers, the environment, and food security. This pilot project is seen as a significant step in leveraging machine learning for advancements in sustainable agriculture.
Potential Positives
- Collaboration with Biographica leverages AI to enhance Cibus’ capabilities in identifying gene editing targets, potentially leading to significant advancements in disease resistance traits for crops.
- This partnership could accelerate the delivery of improved crop varieties, benefiting farmers and contributing to global food security.
- The project aligns with Cibus’ commitment to sustainability and innovation in agriculture, addressing critical disease pressures faced by crops.
Potential Negatives
- The collaboration may highlight Cibus' dependency on external partnerships for technological advancements in gene editing, potentially indicating a lack of internal capabilities in this area.
- The press release does not provide concrete details on timelines or expected outcomes for the pilot project, which could raise concerns about the project's viability and strategic direction.
- Cibus is competing in a highly competitive field where other companies are also innovating, which may dilute the impact and differentiation of their gene editing solutions.
FAQ
What is the focus of the Cibus and Biographica collaboration?
The collaboration aims to advance disease resistance in oilseed rape and Canola through gene editing target identification.
How does Biographica's AI technology benefit this partnership?
Biographica's AI platform helps analyze and prioritize gene targets for disease resistance, enhancing Cibus's crop improvement strategies.
Why is disease resistance important in agriculture?
Disease resistance is crucial for maintaining crop health, yield, and quality, directly impacting food security and sustainable farming practices.
What are the expected outcomes of this partnership?
The partnership aims to accelerate the development of advanced disease-resistant crop varieties for farmers worldwide.
How does Cibus position itself in the agricultural technology sector?
Cibus develops and licenses plant traits using proprietary gene editing technology, focusing on improving productivity and sustainability in major row crops.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBUS Insider Trading Activity
$CBUS insiders have traded $CBUS stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CBUS stock by insiders over the last 6 months:
- CARLO BROOS (Interim CFO) sold 4,647 shares.
- GREGORY FRANCIS WILLIAM GOCAL (Chief Scientific Officer & EVP) has traded it 3 times. They made 0 purchases and 3 sales, selling 6,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CBUS Hedge Fund Activity
We have seen 33 institutional investors add shares of $CBUS stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 566,328 shares (+16.9%) to their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC removed 516,000 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 142,849 shares (+inf%) to their portfolio in Q3 2024
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 116,465 shares (-100.0%) from their portfolio in Q2 2024
- STATE STREET CORP added 93,236 shares (+43.6%) to their portfolio in Q3 2024
- NORTHERN TRUST CORP added 89,521 shares (+179.9%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 81,710 shares (+8.3%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Cibus and Biographica to collaborate on identifying gene editing targets for Cibus’ disease resistance trait development
Biographica’s proprietary AI platform linked with Cibus’ crop editing abilities provide opportunities for discovery and commercial application
SAN DIEGO and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, and Biographica , a UK-based leader in AI and graph machine learning for gene discovery, are pleased to announce a collaborative pilot project focused on advancing disease resistance in oilseed rape and Canola.
This partnership leverages Biographica’s proprietary platform to identify and prioritize targets for gene editing, aiming to develop resistance against critical diseases impacting crop health, yield and quality.
Under this agreement, Biographica will utilize its cutting-edge AI and machine learning technology to analyze gene targets associated with disease resistance in oilseed rape and Canola and set the stage for future crop improvement strategies.
“This collaboration marks a significant milestone in unlocking the potential of advanced machine learning for agricultural innovation,” said Cecy Price, CEO at Biographica. “Combining Biographica’s unique machine learning trait discovery platform with Cibus’ expertise in crop trait development allows us to unlock new insights into disease resistance, paving the way for more resilient crops and sustainable agricultural practices.”
Tony Moran, Senior Vice President for International Development at Cibus, added, “We are excited to work alongside Biographica to identify impactful gene targets, enabling the development of crop varieties that can withstand disease pressure in the field with benefits for farmers, the environment, and food security.”
Dr. Greg Gocal, Executive Vice President and Chief Scientific Officer, added, “We have made plant disease resistance an important pillar of our work. This is a critically important need in farming. Developing durable disease resistance in plants will require identifying multiple modes of action. This partnership with Biographica is an important extension of our work in building our inventory of gene targets associated with developing different modes of action for this important trait.”
The collaboration reflects a commitment by both companies to push the boundaries of crop science and contribute to sustainable agriculture. This pilot project has the potential to accelerate the delivery of improved crop varieties with advanced disease resistant traits to farmers worldwide.
About Biographica
Biographica, Ltd. is a UK-based company specializing in advanced machine learning algorithms for target discovery. Their proprietary Biographica Platform enables researchers to identify and prioritize gene targets effectively, supporting breakthroughs in gene editing and other advanced biological applications.
About Cibus
Cibus is a leading independent plant trait company that develops and licenses plant traits to seed companies for royalties. Cibus is not a seed company, but rather a technology company that uses its proprietary gene editing technology to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus’ strategy is focused on commercializing productivity traits for the world’s major row crops with large acreage such as: canola, rice, and soybean. The Company targets traits that help manage farmers’ seed productivity, economics and sustainability challenges such as weeds, disease, and insects. The United Nations estimates that the impacts from these challenges cost the global economy approximately $300 billion annually. Cibus has a current portfolio of six traits, three of which are in commercial development and four of which are multi-crop traits associated with weed management and disease, including Sclerotinia resistance and a new weed management trait which are in advanced greenhouse and field trial stages.
CIBUS CONTACTS:
INVESTOR RELATIONS
Karen Troeber
ktroeber@cibus.com
858-450-2636
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
media@cibus.com
Colin Sanford
colin@bioscribe.com
203-918-4347
/A%20photo%20of%20a%20Sandisk%20Solid%20State%20Drive%20by%20Top%20Popular%20Vector%20by%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/ServiceNow%20Inc%20building%20in%20Silicon%20Valley-by%20Sundry%20Photography%20via%20iStock.jpg)